TNF blockade uncouples toxicity from antitumor efficacy induced with CD40 chemoimmunotherapy

Agonist CD40 antibodies are under clinical development in combination with chemotherapy as an approach to prime for antitumor T cell immunity. However, treatment with anti-CD40 is commonly accompanied by both systemic cytokine release and liver transaminase elevations, which together account for the...

Descripción completa

Detalles Bibliográficos
Autores principales: Stone, Meredith L., Lee, Jesse, Herrera, Veronica M., Graham, Kathleen, Lee, Jae W., Huffman, Austin, Coho, Heather, Tooker, Evan, Myers, Max I., Giannone, Michael, Li, Yan, Buckingham, Thomas H., Long, Kristen B., Beatty, Gregory L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Clinical Investigation 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8410039/
https://www.ncbi.nlm.nih.gov/pubmed/34101617
http://dx.doi.org/10.1172/jci.insight.146314

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8410039/
https://www.ncbi.nlm.nih.gov/pubmed/34101617
http://dx.doi.org/10.1172/jci.insight.146314

Ejemplares similares